• +1-646-491-9876
    • +91-20-67278686

    Search

    Tyrosine Protein Kinase Receptor UFO-Pipeline Review H1 2017

    Tyrosine Protein Kinase Receptor UFO-Pipeline Review H1 2017

    • Report Code ID: RW0001834415
    • Category Pharmaceuticals
    • No. of Pages 110
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017'; Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes.

    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs) -mediated innate immune response.

    The report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017' outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL) , Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Adrenocortical Carcinoma (Adrenal Cortex Cancer) , Bile Duct Cancer (Cholangiocarcinoma) , Blood Cancer, Bone Metastasis, Colon Carcinoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST) , Head And Neck Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer) , Leukemias, Liposarcoma, Liver Cancer, Melanoma, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM) , Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Skin Cancer, Thrombosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) , Ureter Cancer, Urethral Cancer and Wilms' Tumor (Nephroblastoma) .

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
    - The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    BerGenBio ASA
    Betta Pharmaceuticals Co Ltd
    Celldex Therapeutics Inc
    Exelixis Inc
    Ignyta Inc
    Les Laboratoires Servier SAS
    Mirati Therapeutics Inc
    Ono Pharmaceutical Co Ltd
    Oribase Pharma
    Qurient Co Ltd
    SignalChem Lifesciences Corp
    Takeda Pharmaceutical Company Ltd
    Tolero Pharmaceuticals Inc
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
    Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGB-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGB-324 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BPI-9016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cabozantinib s-malate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CT-053 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CT-413 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gilteritinib fumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glesatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HOPE-777 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody Conjugate to Inhibit AXL Kinase for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ONO-7475 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Q-701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RXDX-106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-49076 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SGI-7079 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sitravatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SLC-0211 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit AXL for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0903 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
    Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
    Featured News & Press Releases
    May 22, 2017: BerGenBio Announces Start of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma
    May 19, 2017: Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017
    Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
    Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
    Mar 06, 2017: Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
    Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    Jan 09, 2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017
    Jan 05, 2017: Mirati Therapeutics Provides Update On Glesatinib Clinical Trial And Pipeline Program
    Jan 05, 2017: Mirati Therapeutics Provides Update On Sitravatinib Clinical Trial And Pipeline Program
    Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance
    Dec 07, 2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
    Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016
    Nov 29, 2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
    Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
    Nov 17, 2016: Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by BerGenBio ASA, H1 2017
    Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
    Pipeline by Celldex Therapeutics Inc, H1 2017
    ipeline by Exelixis Inc, H1 2017
    Pipeline by Ignyta Inc, H1 2017
    Pipeline by Les Laboratoires Servier SAS, H1 2017
    Pipeline by Mirati Therapeutics Inc, H1 2017
    Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Pipeline by Oribase Pharma, H1 2017
    Pipeline by Qurient Co Ltd, H1 2017
    Pipeline by SignalChem Lifesciences Corp, H1 2017
    Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Pipeline by Tolero Pharmaceuticals Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    BerGenBio ASA
    Betta Pharmaceuticals Co Ltd
    Celldex Therapeutics Inc
    Exelixis Inc
    Ignyta Inc
    Les Laboratoires Servier SAS
    Mirati Therapeutics Inc
    Ono Pharmaceutical Co Ltd
    Oribase Pharma
    Qurient Co Ltd
    SignalChem Lifesciences Corp
    Takeda Pharmaceutical Company Ltd
    Tolero Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-receptor-ufo-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-receptor-ufo-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-receptor-ufo-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments